Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel CAR-T for Hematological Malignancies
NCT04191941Phase 1Unknown
- Sponsor
- Timmune Biotech
- Start
- Sep 2019
- Primary completion
- Aug 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Beijing Boren Hospital autologous CAR-T therapy in B-cell non-Hodgkin lymphoma (B-NHL), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM), sponsored by Timmune Biotech. Primary endpoint: Incidence of treatment-related adverse events at 3 months. Status: unknown.
02
Drugs
Beijing Boren Hospital autologous CAR-T therapy
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)acute lymphoblastic leukemia (ALL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04191941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191941.